INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) EXPANDS LEADERSHIP TEAM

Published Oct 28, 2015

BETSY LANE JOINS ISPOR AS CHIEF MARKETING & COMMUNICATIONS OFFICER 

Princeton, NJ—October 28, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that Betsy Lane has been appointed director and chief marketing and communications officer for the organization. Lane will lead ISPOR’s global marketing and communications efforts to help further advance the organization’s mission to promote health economics and outcomes research excellence to improve decision making for health globally. Lane has over 25 years’ experience in the life sciences industry. Prior to joining ISPOR, she served as senior vice president, marketing and communications at Publicis Touchpoint Solutions. Previously, she worked for several medical advertising agencies leading agency teams primarily focused on specialty product launches in the oncology, endocrinology, CNS, and dermatology therapeutic areas. Lane began her career working as a pharmaceutical sales representative. While at Johnson & Johnson, she served in a variety of increasingly significant roles, including divisional sales manager and product manager. “We are excited to have Betsy join the ISPOR team,” stated Nancy Berg, chief executive officer and executive director. “Our organization has grown tremendously over the years and we believe that Betsy’s experience will help us to further our mission by more effectively communicating the great work that ISPOR does day in and day out.”

###

Related Stories

Promoting Fairness in Funding Decisions

Jun 24, 2026

Value in Health announced the publication of a special themed section of research papers that offer new tools to help health policy makers weigh fairness alongside cost-effectiveness when deciding which treatments and programs to fund.

Listening to Patients in the Real World

Jun 23, 2026

Value in Health, the official journal of ISPOR announced today the publication of an ISPOR Good Practices Report outlining 9 areas to strengthen the robustness, transparency, and feasibility of real-world patient-reported outcomes studies.

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×